In this trial, patients with CD30-positive PTCL were randomized between a treatment with brentuximab vedotin, cyclophosphamide, doxorubicin, and prednisone (BV-CHP) or standard cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) regimen [79]. This evidence concerns the gene TNFRSF8 and mature T-cell and NK-cell non-Hodgkin lymphoma.